Category: biotech

.Capricor Therapeutics is taking a success lap for their phase 2 Duchenne muscular dystrophy (DMD) test. At 3 years, the San Diego-based provider’s tissue therapy

.Possessing actually gathered up the U.S. rights to Capricor Therapies’ late-stage Duchenne muscular dystrophy (DMD) therapy, Asia’s Nippon Shinyaku has validated $35 million in cash

.RNA biotech CAMP4 Therapies has actually marked out think about a $67 million IPO, with inflammation-focused Upstream Biography securing its personal objectives at $182 thousand.While

.BridgeBio Pharma is actually lowering its genetics therapy budget and also pulling back from the modality after observing the results of a phase 1/2 clinical

.Some patients with non-small cell bronchi cancer cells (NSCLC) possess mutations in a gene called human epidermal development element receptor 2 (HER2), which drives their

.As summer months heat energy relies on cool winds, hopes that this year will deliver prevalent sector comfort have actually frittered away, along with quarterly

.Biogen has actually conducted the final rites to its own collaboration with Sage Therapeutics on SAGE-324, scrapping the partnership in the consequences of a failed

.Biogen as well as UCB’s rely on improving in to period 3 on the back of a broken study seeks to have paid off, with

.BioMarin is actually incorporating kindling to the R&ampD fire, assaulting a suit with CAMP4 Therapeutics for liberties to decide on pair of intendeds recognized due

.BioAge Labs is generating practically $200 thousand through its own Nasdaq IPO today, with the earnings earmarked for taking its own lead weight problems drug